Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit and Capitalization (Detail Textuals)

v3.10.0.1
Stockholders' Deficit and Capitalization (Detail Textuals) - USD ($)
 1 Months Ended 9 Months Ended
Feb. 28, 2018
Feb. 16, 2018
Jan. 31, 2018
Jan. 19, 2018
Sep. 30, 2018
Equity [Line Items]          
Common stock gross proceeds $ (1,750,000)   $ (1,500,000)   $ (3,250,000)
Maximum aggregate gross proceeds         900,000
Securities purchase agreement | Emerald Health Sciences Inc          
Equity [Line Items]          
Common stock issued   15,000,000   15,000,000  
Number of warrants issued   20,400,000   20,400,000  
Warrant exercise price   $ 0.10   $ 0.10  
Common stock gross proceeds       $ 1,500,000  
Term of warrants   5 years      
Legal reimbursement fees         $ 25,000
Securities purchase agreement | Emerald Health Sciences Inc | Accredited investor          
Equity [Line Items]          
Common stock issued   2,500,000      
Number of warrants issued   3,400,000      
Warrant exercise price   $ 0.10      
Common stock gross proceeds   $ 1,750,000      
Term of warrants   5 years      
Securities purchase agreement | Emerald Health Sciences Inc | Promissory Note          
Equity [Line Items]          
Maximum aggregate gross proceeds       $ 900,000  
Conversion price, per share (in dollars per share)       $ 0.10  
Number of common shares issued in conversion of bridge loan       9,000,000  
Subsequent financing purchase price, description       The Securities Purchase Agreement also provides that in the case of a subsequent financing in which the purchase price is less than $0.10 per share, Emerald shall be issued additional shares in order to protect against anti-dilution.